We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tumor resensitization to erlotinib following brief substitution of cetuximab.
- Authors
Epstein, R J; Leung, T W
- Abstract
Targeted inhibition of epidermal growth factor receptors (EGFR) is becoming a standard anticancer treatment in defined clinical scenarios. EGFR inhibition may be achieved either by small-molecule orally bioavailable tyrosine kinase inhibitors, such as gefitinib or erlotinib, or else by large-molecule receptor antibodies, such as cetuximab or panitumumab. Here, we describe a case of pancreatic cancer in which the small-molecule EGFR antagonist erlotinib was used before and after the EGFR antibody cetuximab, with unexpected potentiation of both toxic and therapeutic sequelae.
- Publication
Cancer chemotherapy and pharmacology, 2008, Vol 62, Issue 6, p1111
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-008-0698-6